Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. DMK Pharmaceuticals's selling, general, & admin. expense for the
three
months ended in Sep. 2023 was $2.52 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Sep. 2023 was $14.48 Mil.
DMK Pharmaceuticals (OTCPK:DMKPQ) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
DMK Pharmaceuticals Selling, General, & Admin. Expense Related Terms
DMK Pharmaceuticals Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for DMK Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals Selling, General, & Admin. Expense Chart
DMKPQ vs CNNC, THCT, VFRM: Selling, General, & Admin. Expense Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals Selling, General, & Admin. Expense vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's Selling, General, & Admin. Expense falls into.
DMK Pharmaceuticals Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $14.48 Mil mean?
DMK Pharmaceuticals (DMKPQ) has a Selling, General, & Admin. Expense of $14.48 Mil as of Sep. 2023. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on DMK Pharmaceuticals and its competitors.
Is DMK Pharmaceuticals' Selling, General, & Admin. Expense too high?
DMK Pharmaceuticals' current Selling, General, & Admin. Expense is $14.48 Mil. Overall, DMK Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does DMK Pharmaceuticals' Selling, General, & Admin. Expense compare to CNNC and THCT?
DMK Pharmaceuticals' Selling, General, & Admin. Expense of $14.48 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on DMK Pharmaceuticals and its competitors. DMK Pharmaceuticals's current Selling, General, & Admin. Expense is $14.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DMK Pharmaceuticals stock overvalued right now?
DMK Pharmaceuticals (DMKPQ) has a current Selling, General, & Admin. Expense of $14.48 Mil. The current Selling, General, & Admin. Expense is $14.48 Mil. DMK Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For DMK Pharmaceuticals (DMKPQ), the current Selling, General, & Admin. Expense is $14.48 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score
Get the complete analysis for DMKPQ
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMKPQ has been successfully added to your 
